Incannex Healthcare (IXHL) Competitors

Incannex Healthcare logo
$1.75 +0.01 (+0.57%)
Closing price 04:00 PM Eastern
Extended Trading
$1.78 +0.03 (+1.71%)
As of 05:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IXHL vs. NRXP, CPIX, BGM, PLYX, and ICCC

Should you buy Incannex Healthcare stock or one of its competitors? Incannex Healthcare's main competitors and comparable companies include NRx Pharmaceuticals (NRXP), Cumberland Pharmaceuticals (CPIX), BGM Group (BGM), Polaryx Therapeutics (PLYX), and ImmuCell (ICCC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Incannex Healthcare compare to NRx Pharmaceuticals?

Incannex Healthcare (NASDAQ:IXHL) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Incannex Healthcare has a net margin of 0.00% compared to NRx Pharmaceuticals' net margin of -458.48%. NRx Pharmaceuticals' return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Incannex HealthcareN/A -20.27% -19.15%
NRx Pharmaceuticals -458.48%N/A -50.74%

Incannex Healthcare has a beta of 7, indicating that its share price is 600% more volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.11, indicating that its share price is 111% more volatile than the broader market.

Incannex Healthcare currently has a consensus price target of $18.00, suggesting a potential upside of 934.48%. NRx Pharmaceuticals has a consensus price target of $35.00, suggesting a potential upside of 1,328.57%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Incannex Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Incannex Healthcare
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67
NRx Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

Incannex Healthcare has higher earnings, but lower revenue than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Incannex Healthcare$90K242.63-$19.30M-$1.24N/A
NRx Pharmaceuticals$1.23M86.95-$28.62M-$0.55N/A

In the previous week, NRx Pharmaceuticals had 14 more articles in the media than Incannex Healthcare. MarketBeat recorded 15 mentions for NRx Pharmaceuticals and 1 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 2.39 beat NRx Pharmaceuticals' score of 0.42 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company Overall Sentiment
Incannex Healthcare Very Positive
NRx Pharmaceuticals Neutral

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 9.1% of Incannex Healthcare shares are owned by insiders. Comparatively, 4.9% of NRx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Incannex Healthcare and NRx Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Incannex Healthcare compare to Cumberland Pharmaceuticals?

Incannex Healthcare (NASDAQ:IXHL) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Cumberland Pharmaceuticals has higher revenue and earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Cumberland Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Incannex Healthcare$90K242.63-$19.30M-$1.24N/A
Cumberland Pharmaceuticals$44.52M1.95-$2.84M$4.491.29

Cumberland Pharmaceuticals has a net margin of 274.38% compared to Incannex Healthcare's net margin of 0.00%. Cumberland Pharmaceuticals' return on equity of -19.50% beat Incannex Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Incannex HealthcareN/A -20.27% -19.15%
Cumberland Pharmaceuticals 274.38%-19.50%-8.12%

Incannex Healthcare currently has a consensus target price of $18.00, suggesting a potential upside of 934.48%. Given Incannex Healthcare's stronger consensus rating and higher probable upside, equities analysts plainly believe Incannex Healthcare is more favorable than Cumberland Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Incannex Healthcare
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67
Cumberland Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 9.1% of Incannex Healthcare shares are owned by company insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Incannex Healthcare has a beta of 7, suggesting that its share price is 600% more volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market.

In the previous week, Cumberland Pharmaceuticals had 2 more articles in the media than Incannex Healthcare. MarketBeat recorded 3 mentions for Cumberland Pharmaceuticals and 1 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 2.39 beat Cumberland Pharmaceuticals' score of 0.79 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company Overall Sentiment
Incannex Healthcare Very Positive
Cumberland Pharmaceuticals Positive

Summary

Cumberland Pharmaceuticals beats Incannex Healthcare on 10 of the 16 factors compared between the two stocks.

How does Incannex Healthcare compare to BGM Group?

BGM Group (NASDAQ:BGM) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

In the previous week, BGM Group had 1 more articles in the media than Incannex Healthcare. MarketBeat recorded 2 mentions for BGM Group and 1 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 2.39 beat BGM Group's score of 0.86 indicating that Incannex Healthcare is being referred to more favorably in the news media.

Company Overall Sentiment
BGM Group Positive
Incannex Healthcare Very Positive

0.4% of Incannex Healthcare shares are held by institutional investors. 58.7% of BGM Group shares are held by insiders. Comparatively, 9.1% of Incannex Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Incannex Healthcare has a consensus target price of $18.00, indicating a potential upside of 934.48%. Given Incannex Healthcare's stronger consensus rating and higher possible upside, analysts plainly believe Incannex Healthcare is more favorable than BGM Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BGM Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Incannex Healthcare
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67

BGM Group's return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
BGM GroupN/A N/A N/A
Incannex Healthcare N/A -20.27%-19.15%

BGM Group has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 7, meaning that its stock price is 600% more volatile than the broader market.

Incannex Healthcare has lower revenue, but higher earnings than BGM Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BGM Group$37.92M2.83-$19.94MN/AN/A
Incannex Healthcare$90K242.63-$19.30M-$1.24N/A

Summary

Incannex Healthcare beats BGM Group on 8 of the 13 factors compared between the two stocks.

How does Incannex Healthcare compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Polaryx Therapeutics presently has a consensus target price of $7.67, suggesting a potential upside of 379.17%. Incannex Healthcare has a consensus target price of $18.00, suggesting a potential upside of 934.48%. Given Incannex Healthcare's higher possible upside, analysts plainly believe Incannex Healthcare is more favorable than Polaryx Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Polaryx Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60
Incannex Healthcare
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67

Polaryx Therapeutics has higher earnings, but lower revenue than Incannex Healthcare. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Polaryx TherapeuticsN/AN/A-$8.98M-$0.08N/A
Incannex Healthcare$90K242.63-$19.30M-$1.24N/A

In the previous week, Polaryx Therapeutics had 9 more articles in the media than Incannex Healthcare. MarketBeat recorded 10 mentions for Polaryx Therapeutics and 1 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 2.39 beat Polaryx Therapeutics' score of 0.68 indicating that Incannex Healthcare is being referred to more favorably in the news media.

Company Overall Sentiment
Polaryx Therapeutics Positive
Incannex Healthcare Very Positive

0.4% of Incannex Healthcare shares are owned by institutional investors. 45.8% of Polaryx Therapeutics shares are owned by insiders. Comparatively, 9.1% of Incannex Healthcare shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Incannex Healthcare's return on equity of -20.27% beat Polaryx Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Polaryx TherapeuticsN/A -136.66% -120.26%
Incannex Healthcare N/A -20.27%-19.15%

Summary

Polaryx Therapeutics beats Incannex Healthcare on 7 of the 13 factors compared between the two stocks.

How does Incannex Healthcare compare to ImmuCell?

Incannex Healthcare (NASDAQ:IXHL) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Incannex Healthcare currently has a consensus price target of $18.00, indicating a potential upside of 934.48%. Given Incannex Healthcare's higher possible upside, research analysts clearly believe Incannex Healthcare is more favorable than ImmuCell.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Incannex Healthcare
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67
ImmuCell
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Incannex Healthcare has a beta of 7, meaning that its share price is 600% more volatile than the broader market. Comparatively, ImmuCell has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

In the previous week, ImmuCell had 5 more articles in the media than Incannex Healthcare. MarketBeat recorded 6 mentions for ImmuCell and 1 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 2.39 beat ImmuCell's score of 0.94 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company Overall Sentiment
Incannex Healthcare Very Positive
ImmuCell Positive

ImmuCell has higher revenue and earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Incannex Healthcare$90K242.63-$19.30M-$1.24N/A
ImmuCell$27.64M3.73-$1.04M$0.2056.65

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 9.1% of Incannex Healthcare shares are owned by insiders. Comparatively, 5.7% of ImmuCell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ImmuCell has a net margin of 5.66% compared to Incannex Healthcare's net margin of 0.00%. ImmuCell's return on equity of 6.25% beat Incannex Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Incannex HealthcareN/A -20.27% -19.15%
ImmuCell 5.66%6.25%4.15%

Summary

ImmuCell beats Incannex Healthcare on 10 of the 16 factors compared between the two stocks.

Get Incannex Healthcare News Delivered to You Automatically

Sign up to receive the latest news and ratings for IXHL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IXHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IXHL vs. The Competition

MetricIncannex HealthcarePharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$21.96M$13.38B$7.59B$11.72B
Dividend YieldN/A2.58%2.47%4.48%
P/E Ratio-1.4127.9733.5830.13
Price / Sales244.036.788.255.59
Price / CashN/A15.6321.0121.90
Price / Book0.335.394.443.72
Net Income-$19.30M$2.88B$3.50B$393.88M
7 Day Performance-11.62%-5.22%-6.53%-6.07%
1 Month Performance-37.94%-4.79%-4.93%-7.38%
1 Year Performance-83.32%-7.34%-1.73%-7.48%

Incannex Healthcare Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IXHL
Incannex Healthcare
2.8395 of 5 stars
$1.75
+0.6%
$18.00
+928.6%
-82.9%$21.96M$90KN/A12
NRXP
NRx Pharmaceuticals
2.5788 of 5 stars
$2.15
-1.8%
$35.00
+1,527.9%
+16.1%$99.51M$1.23MN/A29
CPIX
Cumberland Pharmaceuticals
1.4035 of 5 stars
$5.21
-11.4%
N/A+205.3%$99.34M$44.52M1.1693
BGM
BGM Group
1.1849 of 5 stars
$7.91
+0.3%
N/A-96.9%$97.69M$37.92MN/A298
PLYX
Polaryx Therapeutics
1.9995 of 5 stars
$1.67
-5.6%
$7.67
+359.1%
N/A$93.71MN/AN/A11

Related Companies and Tools


This page (NASDAQ:IXHL) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners